Skip to main content

Astrazeneca Plc ADR(AZN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low65.91
Day High66.43
Open:65.92
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

The Power of Science to Stop a Killer
Investor Brand Network - Mon Aug 8, 11:35AM CDT
Investor Brand Network
Mon Aug 8, 11:35AM CDT
NetworkNewsWire Editorial Coverage : Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114 million adults in this country are at risk from damage caused by the...
The Power of Science to Stop a Killer
PR Newswire - Mon Aug 8, 7:30AM CDT
PR Newswire
Mon Aug 8, 7:30AM CDT
/PRNewswire/ -- Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114 million...
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
Business Wire - Mon Aug 8, 6:00AM CDT
Business Wire
Mon Aug 8, 6:00AM CDT
Preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO ® (osimertinib) plus savolitinib demonstrated an objective response rate (ORR) of 49% (95% confidence interval [CI], 39-59%) in patients with epidermal growth factor...

Latest Articles

BioNTech says repeat doses remain better strategy than adapting its COVID-19 vaccine to new variants